Immunocore CFO Brian Di Donato resigns, effective Dec 31, 2024, to become CEO at private biotech

Immunocore Holdings plc

CFO and Head of Strategy Brian Di Donato resigns effective Dec 31, 2024, to become CEO at a private early-stage biotech in San Diego.
Resignation not due to any disagreement with Immunocore on financials, internal controls, or policies.
Di Donato remains through year-end to ensure smooth transition; formal CFO search initiated.
Di Donato joined over 4 years ago, led IPO and built Finance department.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Di Donato

Chief Financial Officer

IMCR · Immunocore Holdings plc

Effective: 2024-12-31
Filed: August 29, 2024, 7:59 PM ET

Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Di Donato resigned as Chief Financial Officer at Immunocore Holdings plc.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.

View on SEC.gov

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-24-039083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.